Agenus Inc. Current Part of Debt

Current Part of Debt of AGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Part of Debt growth rates and interactive chart. Current debt or short-term debt are a firm's financial obligations that are expected to be paid off within a year. It also includes the portion of long-term debt that is due within a year. It is a part of the overall indebtedness of a company, and is included in Debt/Equity and Debt/Assets ratios.

Highlights and Quick Summary

  • Current Part of Debt for the quarter ending June 29, 2020 was $1.53 Million (a 137.15% increase compared to previous quarter)
  • Year-over-year quarterly Current Part of Debt decreased by -88.94%
  • Annual Current Part of Debt for 2019 was $646 Thousand (a 342.47% increase from previous year)
  • Annual Current Part of Debt for 2018 was $146 Thousand (a -99.29% decrease from previous year)
  • Annual Current Part of Debt for 2017 was $20.6 Million (a 14027.1% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Part of Debt of Agenus Inc.

Most recent Current Part of Debtof AGEN including historical data for past 10 years.

Interactive Chart of Current Part of Debt of Agenus Inc.

Agenus Inc. Current Part of Debt for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $1.53 $0.65
2019 $0.65 $13.85 $13.68 $13.52 $0.65
2018 $0.15 $0.15 $0.15 $0.15 $0.15
2017 $20.64 $19.96 $0.15 $0.15 $20.64
2016 $0.15 $0.15 $0.15 $0.15 $0.15
2015 $0.15 $0.15 $0.15 $0.42 $0.15
2014 $1.26 $6.72 $7.43 $4.08 $1.26
2013 $3.52 $3.26 $2.43 $0.2 $3.52
2012 $0.2 $0.21 $0.21 $0.2 $0.2
2011 $0.2 $0.2 $0.15 $0.15 $0.2
2010 $0.15 $32.56 $0.15 $0.15 $0.15
2009 $0.15 $0.15 $0.15

Business Profile of Agenus Inc.

Sector: Medical
Industry: Drugs
Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.